BetterLife Pharma Inc (F:NPAU) — Stock Price

€0.07 EUR
▲ 104.55% today

BetterLife Pharma Inc (F:NPAU) is currently trading at €0.07 EUR, up 104.55% today. Over the past 52 weeks, shares have ranged between €0.02 and €0.07. This page tracks BetterLife Pharma Inc's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BetterLife Pharma Inc stock valuation.

BetterLife Pharma Inc (NPAU) Stock Price Chart — Daily History & Trading Volume

The chart below tracks BetterLife Pharma Inc's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.

BetterLife Pharma Inc Income Statement — Revenue, Profit & Earnings by Year

BetterLife Pharma Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue €0.00 €0.00 €0.00 €0.00 €0.00
Cost of Revenue
Gross Profit
Research & Development €424.34K €570.95K €2.68 Million €5.42 Million €284.70K
SG&A €4.30 Million €2.64 Million €6.56 Million €4.53 Million €7.56 Million
Total Operating Expenses €4.72 Million €3.21 Million €9.26 Million €9.97 Million €7.95 Million
Operating Income €-4.72 Million €-3.21 Million €-9.26 Million €-9.97 Million €-7.95 Million
EBITDA €-9.29 Million €-11.92 Million €-35.97 Million
EBIT €-9.97 Million €-7.95 Million
Interest Expense €319.47K €50.90K €67.18K €58.34K €40.10K
Income Before Tax €-3.62 Million €-2.90 Million €-9.37 Million €-11.99 Million €-36.35 Million
Income Tax Expense €166.67K
Net Income €-3.52 Million €-2.89 Million €-9.02 Million €-12.16 Million €-36.35 Million

BetterLife Pharma Inc Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes BetterLife Pharma Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets €224.96K €324.75K €74.73K €1.16 Million €1.34 Million
Total Current Assets €224.96K €324.75K €74.73K €1.14 Million €1.33 Million
Cash & Equivalents
Short-term Investments
Net Receivables €11.64K €39.54K €17.20K €324.99K €520.12K
Inventory
Property, Plant & Equipment €18.43K €36.87K
Goodwill
Total Liabilities €7.59 Million €8.02 Million €7.61 Million €5.04 Million €5.95 Million
Total Current Liabilities €7.54 Million €6.83 Million €7.15 Million €4.14 Million €5.85 Million
Long-term Debt €49.12K €327.73K €34.56K
Net Debt €911.54K €290.35K €71.69K €138.93K €345.28K
Total Stockholder Equity €-10.68 Million €-10.81 Million €-10.73 Million €-3.88 Million €-4.61 Million
Retained Earnings €-118.60 Million €-115.08 Million €-112.19 Million €-103.17 Million €-91.01 Million

BetterLife Pharma Inc Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how BetterLife Pharma Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow €-2.02 Million €-2.47 Million €-1.50 Million €-11.20 Million €-7.16 Million
Capital Expenditures €0.00 €0.00 €0.00 €0.00 €10.15K
Free Cash Flow €-2.02 Million €-2.47 Million €-1.50 Million €-11.20 Million €-7.26 Million
Investing Cash Flow €-71.55K
Financing Cash Flow €1.99 Million €2.50 Million €1.34 Million €11.23 Million €4.09 Million
Dividends Paid
Stock-Based Compensation €2.05 Million €500.26K €951.07K €1.23 Million €826.63K
Depreciation €0.00 €0.00 €18.43K €18.44K €342.81K
Change in Cash €-29.20K €29.08K €-165.21K €18.79K €-3.13 Million

BetterLife Pharma Inc Earnings History — EPS Actual vs. Analyst Estimates

Track BetterLife Pharma Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 27, 2026
Dec 29, 2025
Sep 23, 2025
Jun 25, 2025
Dec 27, 2024